HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Tech "Talent Wars" Are Over as More Companies Prioritize Upskilling, General Assembly Report Finds25.2.2026 15:00:00 CET | Press release
83% of tech recruiters believe company success is more dependent on upskilling employees for AI versus hiring new talent, according to The State of Tech Talent 2026 NEW YORK CITY, NY / ACCESS Newswire / February 25, 2026 / Nearly all technology recruiters (96%) say technical roles are still at least a bit difficult to fill, as most (83%) believe their company's success is now more dependent on upskilling their existing employees for AI rather than hiring external talent, according to The State of Tech Talent 2026, the fourth annual report from AI training provider General Assembly, an LHH brand. "The AI skills gap is growing too fast for companies to hire their way out," said Daniele Grassi, CEO of General Assembly. "Continuous, incremental and role-specific learning is the only way to keep up with the pace of technology change. Growing investment in upskilling reflects leaders' realization that their existing employees bring the business context, institutional knowledge and cultural n
Around Half of Firms' Revenue Depends on Winning RFPs, but Many Lack Scalable Proposal Management Processes, QorusDocs Study Finds25.2.2026 15:00:00 CET | Press release
63% report higher RFP volumes - but up to 20% go unfinished due to resource constraints as proposal teams see 25 to 50% workload spikes SEATTLE, WA / ACCESS Newswire / February 25, 2026 / As B2B buying has become more structured, consensus-driven and risk-averse, proposals and RFPs have moved from a back-office task to a primary driver of revenue at professional services firms, according to new research from QorusDocs, a leader in AI-powered value and proposal management software. Once viewed as a downstream support function, proposal management, now directly shapes pipeline health, win rates and revenue outcomes. As AI disrupts the traditional billable-hour model and prompts corporate clients to question fees, proposal operations have emerged as a critical lever to protect margins and capture growth. However, growing RFP volumes have driven a 25 to 50% workload spike for proposal teams at most organizations. "Time, not intent, has become the primary constraint for modern proposal team
Assembly Chosen to Power Global Paid Media and Amazon Growth for Jabra24.2.2026 15:50:00 CET | Press release
LONDON, GB / ACCESS Newswire / February 24, 2026 / Assembly, the global omnichannel agency built to make brands perform, has been appointed by Jabra, world leading brand in audio, video, and collaboration solutions, as its global paid media agency and lead partner for Amazon services following a competitive pitch process. Assembly's remit spans full-funnel paid media across search, social, display, video, and retail media, alongside Amazon strategy and marketplace operations, to fuel Jabra's next phase of global growth. Pitch Consultants, Tuffon Hall Consultancy, commented: "This was an exceptionally competitive process, and Jabra's new move towards a direct-to-consumer model marks a major shift for the business. Assembly impressed with a powerful proposition, using their proprietary platform STAGE to create a true intelligence engine for Jabra that supports smarter, more connected growth." Why Jabra chose Assembly Assembly was selected for its ability to connect brand and performance,
GA-ASI Develops Long-Range Weapons Capabilities for MQ-9B23.2.2026 13:10:00 CET | Press release
Industry Leading UAS Expands Mission Roles To Include Naval Strike SAN DIEGO, CA / ACCESS Newswire / February 23, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®. Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons. "MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long
GA-ASI and USAF Demonstrate Manned-Unmanned Teaming With F-22 and MQ-20 In Joint Autonomy Exercise23.2.2026 13:05:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms. The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands. "We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to ut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom